ArticleCell systems2026
Deep coverage and extended sequence reads obtained with a single archaeal protease expedite de novo protein sequencing by mass spectrometry.
Article in Cell systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Generalizable Direct Protein Sequencing With InstaNexus.Molecular & cellular proteomics : MCP · 2026Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to sequence proteins without reliance on a genomic template defines a critical frontier in proteomics. This approach, known as de novo protein sequencing, is essential for applications in antibody sequencing, microbiome proteomics, and antigen discovery, which require accurate reconstruction of target sequences. To advance this field, we here explore two hyperthermoacidic archaeal (HTA) proteases for de novo antibody sequencing, benchmarking them against trypsin and chymotrypsin. Each HTA-protease generated about five times more unique peptide reads than trypsin or chymotrypsin, providing high redundancy across all complementarity-determining regions. Combined with EAciD fragmentation on a ZenoTOF, this methodology enabled complete, unambiguous antibody sequencing. De novo analysis showed much higher alignment scores and reduced the sequence errors by using the HTA-generated data. With short digestion times, minimal sample cleanup, and analysis in just a single liquid chromatography-mass spectrometry (LC-MS/MS) run, this streamlined single-protease approach delivers a scalable and efficient strategy for de novo protein sequencing across diverse applications. A record of this paper's transparent peer review process is included in the supplemental information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.